Skip to main content
. 2019 Oct 15;9:1059. doi: 10.3389/fonc.2019.01059

Figure 4.

Figure 4

Evaluating the efficacy of the five pseudogenes risk signature in the validation cohort. (A) Survival curves for high-risk and low-risk groups classified by the risk signature in the validation cohort. (B) ROC curves for the 1-, 3-, and 5-year survival according to the five-pseudogene risk signature in the validation cohort. (C) Glioma expression profiles of the five pseudogenes, risk score distributions and patient survival in the validation cohort.